A brand new Danish medtech company with 20 years of research and experience behind it is entering the stock exchange in March, where it wants to raise DKK 32 million (USD 4.7 million) to kickstart sales of a new product, which aims to make it easier to monitor and diagnose illlnesses.
On Wednesday, the Danish Medicines Agency revoked some elements of the family-owned medicine producer Scanpharm's license due to long-term problems with the company's quality control.
Carste Hellmann, CEO of ALK, is excited about the company's financial report, where earnings in particular were a positive surprise. The difference between deficit and profit depends on how much the company spends on clinical trials from now on, he says.
After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.
When the majority of the rehab market is accumulated into public calls for tenders, it can attract large and strong competitors to Danish businesses. This is the fear of a Danish manufacturer, whilst the industry association reccommends that companies keep calm - but only for a while.
Novo Nordisk is on the hunt for collaborations and purchases for the company's pipeline from a newly opened office in Boston. The office has no concrete budget, just a goal of strengthening and diversifying Novo Nordisk's product range.
While Lundbeck's key products continue to grow, the company's leadership are gearing up for a new product launch next year - and that will require bigger changes, especially in the sales and marketing departments, says CEO Deborah Dunsire.
Coloplast had to include an extraordinary loss of DKK 400 million (USD 59.4 million) in its year-end statement due to court cases in the USA. Financial director Anders Lonning-Skovgaard is "very satisfied" with the accounts, but cannot say for sure whether the court case expenses have been paid.
Chemometec and CEO Michael Eising have launched and sold the first unit of cell counter NC-202, which is an upgrade of the company's best-selling product. The firm is starting sales at brand new biotech companies.
Biotech company Union Therapeutics has treated the first patient in its phase II trial of the company's drug candidate, which is a potential new treatment for atopic dermatitis.
Novo Nordisk CEO Lars Fruergaard Jørgensen is "very satisfied" with the company's sale of its GLP-1 agonist Ozempic after seven quarters on the market. But he also believes that the company must make the market for the drug even bigger.
58-year-old Anker Lundemose has built his carrer in the biotech industry on saying yes when job opportunities came knocking - without dwelling too much on the risk. It started when he left a comfortable position at Novo Nordisk to found the forerunner to Santaris in 1998.
Analysts believe that WS Audiology's shelving of its prestige project, the development of a hearing aid powered by fuel cells, is a serious setback. The company has refused to comment further on the decision, stating "We have said everything that we want to be said".
The establishment of a central, shared European database, Eudamed, which will increase the control and surveillance of medtech products on the market in Europe, is delayed by two years. The medtech industry is "taking the situation very seriously".
Resother Pharma, which is developing a new type of anti-inflammatory medicine, has secured DKK 16 million (USD 2.4 million) - enough to take the company's first drug to clinical trials.
Industry association Dansk Biotech and Roche fear that the dialogue between the Department of Trade and the industry will suffer, as the head of the ministry's life science department changes job.
Draupnir Bio, which is developing a pill for blood clots in the heart, has received DKK 225 million from four european venture funds including Novo Seeds.
58-year-old Anker Lundemose has built his carrer in the biotech industry on saying yes when job opportunities came knocking - without dwelling too much on the risk. It started when he left a comfortable position at Novo Nordisk to found the forerunner to Santaris in 1998.
Hearing aid firm WS Audiology, that was formed through the merger of Sivantos and Widex, is saying farewell to its Nordic director, who has been at the firm for 22 years. The hot seat is being filled by an internal candidate who came to the company from Coloplast last year.
Over the last few years, Össur's prosthetics business has sprinted ahead of its support products, and CEO Jon Sigurdsson expects this development to continue in the future. In his experience, technological competition in the development of prostheses has taken out most of the competitors.
Lars Marcher's firing and the subsequent turmoil were unpleasant events to witness, says Ambu heir Simon Hesse Hoffmann, who received quite a few comments during that time. Today his relationship with the former CEO is "uncomplicated", he says.
After years of development, biotech company Expres2ion is ready with a new version of its manufacturing system, which according to the company CEO is going to "significantly" strengthen the company's position and the development of the vaccination and immune therapy market.
While public health systems are guilty of slowing down growth in the prosthetic market, understanding and accept of costly, advanced prostheses continue to grow, says Össur CEO. He expects buyers to only seek exclusive prosthetic devices sometime in the next 20 years.
The Copenhagen-based biotech company Pancryos is working on a cell therapy to cure type 1 diabetes. The people behind it believe they have discovered a method that can outperform competitors.
Emmanuel Dulac, CEO of Zealand Pharma, is very satisfied that the company has obtained a drug candidate against inflammatory bowel diseases by so far paying nothing. The drug may compete for a share of a billion dollar market.
